PharmaPoint: Alzheimer’s Disease – Global Drug Forecast and Market Analysis to 2026
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Alzheimer’s disease (AD) is a progressive neurodegenerative disease that is characterized by impaired memory and thinking (known as dementia), and functional decline. With a rapidly accelerating worldwide prevalence, there is a growing societal pressure for curative treatment for AD patients. The burden of AD encompasses clinical burden to patients as well as economic burden to payers and patients and caregiver burden, adding to the urgent need for improved AD therapy. Significant efforts are being made to develop a new treatment for AD, as current pharmacologic management is known to only provide a temporary improvement in symptoms.
GlobalData estimates the 2016 sales for AD at approximately $3.0B across the 7MM covered in this report.
The AD pipeline activity is strong, with twenty active Phase III (or Phase II/III) pipeline agents, most notable drug classes of which being passive immunotherapies and BACE inhibitors. These late-phase drugs also include those targeted for AD-linked agitation and cognitive impairments. Despite the fierce competition, GlobalData expects AD drug development to continue to see considerable struggles until reliable biomarkers and diagnostics are developed. Nevertheless, the treatment landscape of AD is expected to see a substantial change during the forecast period of 2016-2026.
Scope
Overview of AD: including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.
Annualized AD market revenue, cost of therapy per patient, and treatment usage patterns in three patient segments (including mild cognitive impairment, mild AD, moderate AD, and severe AD), forecast from 2016 to 2026.
Key topics covered: strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the AD therapeutics market
Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for AD therapy. The most promising candidate in Phase III (and Phase II/III) development is profiled.
Analysis of the current and future market competition in the global AD therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to Buy
The report will enable you to:
Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
Develop business strategies by understanding the trends shaping and driving the global AD therapeutics market.
Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global AD therapeutics market in the future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Abbvie
AC Immune
Acadia
Actinogen Medical
Adamas Pharmaceuticals
Allergan
Amgen
Archer Pharmaceuticals
AstraZeneca
Ausio Pharmaceuticals
Axovant
AZ Therapies
BioArctic NeuroScience AB
Biogen
Biogen
Bionomics
Boehringer Ingelheim
Boehringer Ingelheim
Bristol-Myers Squibb
Charsire Biotechnology Corp
Chugai
Cytos Biotechnology
Daiichi Sankyo
Eisai
Eli Lilly
Enzymotec
Glovia Co
Grifols
ImmunoBrain
Checkppoint
IntraCellular Therapies
Ionis
Janssen
Kyowa Hakko Kirin
Ligand
Lundbeck
Lupin
Mediti Pharma Inc
Merck & Co
Merz
Metabolic Therapy Inc
MorphoSys
Nature Cell
Nature Cell
Neurim Pharmaceuticals
Neurimmune
Neurotrope BioScience
Novartis
Ono Pharmaceutical
Orion Oyj
Otsuka
Pfizer
PharmatrophiX
Probiodrug AG
Proclara Biosciences
Purdue Pharma
QR Pharm
QR Pharma
Roche
Shionogi
Suven Life Sciences
T3D Therapeutics
Takeda
TauRx
Tetra Discovery Partners
Toyama Chemical
vTv Therapeutics
Zinfandel
Table of Contents
Table
Figures
Frequently asked questions
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.